Novo pays $300 million upfront for HRS-1596, and the OCTANE trial reports 4.1% average weight loss after patients switched from injections to oral semaglutide.
Recap by typeshit. Full story at AD HOC NEWS.
A short piece on how cravings and snacking urges may change for people taking GLP-1 drugs. Details are thin, so tap through for the full story.
Philstar Life looks at famous names linked to Ozempic for weight loss. Only a search title came through, so details are thin until you open the source.
An international food and agribusiness expert links growing interest in fibre to the spread of GLP-1 drugs. Details are thin beyond the claim itself.
Early trial results suggest the shot could one day help people hold onto weight loss after they come off GLP-1 drugs.
As more people get weight loss drugs through telehealth, the pharmacies making compounded versions are drawing scrutiny. TIME looks at what buyers should know.
The update backs the drugs alongside lifestyle programs instead of after they fail, and advises against stopping them once they work, a shift for millions of veterans.
Loading…